Invesaro

Stocks Comparison

Alpha Teknova vs Trinity Biotech: revenue, profit, margins and growth compared

Alpha Teknova brought in $40.5M of revenue in fiscal 2025, Trinity Biotech $61.6M in fiscal 2024. Revenue changed by +7.4% at Alpha Teknova and +8.3% at Trinity Biotech on the year before, so Trinity Biotech grew faster. Alpha Teknova kept -42.6% of its revenue as net profit, Trinity Biotech -51.6%. Free cash flow was -$9.8M at Alpha Teknova and -$4.6M at Trinity Biotech.

Side by side, latest fiscal year

TKNOTRIB
Fiscal year endedFY2025 (December 31, 2025)FY2024 (December 31, 2024)
Revenue$40.5M$61.6M
Revenue growth+7.4%+8.3%
Net income-$17.3M-$31.8M
Net margin-42.6%-51.6%
Free cash flow-$9.8M-$4.6M
Free cash flow margin-24.2%-7.5%
Earnings per share (diluted)-$0.32n/a
Cash$5.9M$5.2M
Debt$13.1Mn/a
Price to earningsn/an/a
Market value$500.9Mn/a
Dividend yieldn/an/a
Rank by revenue in sector#391 of 646 · Health care#358 of 646 · Health care

Over the years

Revenue
TKNO FY2021: $31.3MTKNO FY2021: $36.9MTKNO FY2022: $41.4MTKNO FY2023: $36.7MTKNO FY2024: $37.7MTKNO FY2025: $40.5MTRIB FY2017: $99.1MTRIB FY2018: $97MTRIB FY2019: $90.4MTRIB FY2020: $102MTRIB FY2021: $81.1MTRIB FY2022: $62.5MTRIB FY2023: $56.8MTRIB FY2024: $61.6MFY17FY18FY19FY20FY21FY22FY23FY24FY25
TKNO $40.5MTRIB $61.6M
Net income
TKNO FY2021: $3.6MTKNO FY2021: -$9.8MTKNO FY2022: -$47.5MTKNO FY2023: -$36.8MTKNO FY2024: -$26.7MTKNO FY2025: -$17.3MTRIB FY2017: -$40.3MTRIB FY2018: -$22.1MTRIB FY2019: -$28.9MTRIB FY2020: -$6.4MTRIB FY2021: $875KTRIB FY2022: -$41MTRIB FY2023: -$24MTRIB FY2024: -$31.8MFY17FY18FY19FY20FY21FY22FY23FY24FY25
TKNO -$17.3MTRIB -$31.8M
Net margin
TKNO FY2021: 11.4%TKNO FY2021: -26.6%TKNO FY2022: -114.6%TKNO FY2023: -100.3%TKNO FY2024: -70.9%TKNO FY2025: -42.6%TRIB FY2017: -40.6%TRIB FY2018: -22.8%TRIB FY2019: -32.0%TRIB FY2020: -6.3%TRIB FY2021: 1.1%TRIB FY2022: -65.6%TRIB FY2023: -42.3%TRIB FY2024: -51.6%FY17FY18FY19FY20FY21FY22FY23FY24FY25
TKNO -42.6%TRIB -51.6%
Revenue growth
TKNO FY2021: +17.9%TKNO FY2022: +12.3%TKNO FY2023: -11.4%TKNO FY2024: +2.9%TKNO FY2025: +7.4%TRIB FY2018: -2.1%TRIB FY2019: -6.8%TRIB FY2020: +12.8%TRIB FY2021: -20.4%TRIB FY2022: -23.0%TRIB FY2023: -9.1%TRIB FY2024: +8.3%FY18FY19FY20FY21FY22FY23FY24FY25
TKNO +7.4%TRIB +8.3%
Free cash flow
TKNO FY2021: -$3MTKNO FY2021: -$28.9MTKNO FY2022: -$55.5MTKNO FY2023: -$26.7MTKNO FY2024: -$13.5MTKNO FY2025: -$9.8MTRIB FY2017: $4.4MTRIB FY2018: -$299KTRIB FY2019: $3.3MTRIB FY2020: $20.6MTRIB FY2021: $11.4MTRIB FY2022: -$2MTRIB FY2023: -$12.4MTRIB FY2024: -$4.6MFY17FY18FY19FY20FY21FY22FY23FY24FY25
TKNO -$9.8MTRIB -$4.6M

Fiscal years as each company reports them; the two may end in different months.

Questions about Alpha Teknova and Trinity Biotech

Which is bigger by revenue, Alpha Teknova or Trinity Biotech?

Trinity Biotech is bigger by revenue: $61.6M in fiscal 2024, against $40.5M for Alpha Teknova in fiscal 2025.

Which keeps more of its revenue as profit, Alpha Teknova or Trinity Biotech?

Alpha Teknova had a net margin of -42.6% in fiscal 2025; Trinity Biotech had -51.6% in fiscal 2024.

Which grew revenue faster, Alpha Teknova or Trinity Biotech?

In their latest fiscal years revenue changed by +7.4% at Alpha Teknova and +8.3% at Trinity Biotech.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies